Table 1.

In vivo tumor growth in three models treated with vehicle, oxaliplatin, irinotecan, cabazitaxel, regorafenib or capecitabine with number of animals with tumor growth, survival, amount of tumor and number of animals excluded and for what reason

	Vehicle	Oxaliplatin (mg/kg	Irinotecan (mg/kg)	Cabazitaxel (mg/kg)		Regorafenib (mg/kg)			Capecitabine (mg/kg)
		5	60	15	30	10	30	60	359	755
PMP-2
Tumor growth/ total number of animals	12/12	1/6	6/6	3/6	2/5		5/5	6/6	5/6
Survival (days, mean)	39	100	68	100	97		62	57	67
Tumor (g), mean (SEM)	4.3 (0.4)	0.4 (0.4)	4.6 (0.3)	1.2 (0.7)	1.4 (0.9)		2.6 (0.9)	4.1 (0.8)	4.1 (0.8)
# of mice excluded					1*		1***
PMCA-1
Tumor growth/ total number of animals	18/18	0/6	5/6	3/6	1/6	12/12			6/6
Survival (days, mean)	44	84	96	91	103	63			51
Tumor (g), mean (SEM)	5.3 (0.3)	0 (0)	2.6 (1.0)	2.3 (0.9)	0.1 (0.1)	4.3 (0.4)			5.70 (0.3)
PMCA-3
Tumor growth/ total number of animals	24/24	0/5	6/6	9/10	5/5		10/11	6/6	11/11	5/5
Survival (days, mean)	37	100	74	68	75		51	46	45	44
Tumor (g), mean (SEM)	4.7 (0.3)	0	2.8 (0.6)	3.6 (0.5)	4.0 (0.5)		3.6 (0.5)	3.9 (0.3)	4.0 (0.4)	4.2 (0.4)
# of mice excluded		1**			1**		1**		1**	1**

(SEM, Standard error of the mean)

^*Wrong treatment given.

^**Mucin not weighed.

^***No tumor growth, only ascites.